| CIGEX | RNPCX | CIGEX / RNPCX | |
| Total Expense Ratio | 1.15 | 1.06 | 108% |
| Annual Report Gross Expense Ratio | 1.17 | 1.06 | 110% |
| Fund Existence | 19 years | 23 years | - |
| Gain YTD | 17.171 | 20.892 | 82% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 1000000 | 250 | 400,000% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 160M | 165B | 0% |
| Annual Yield % from dividends | 0.00 | 0.21 | - |
| Returns for 1 year | 6.20 | 14.14 | 44% |
| Returns for 3 years | 64.61 | 49.55 | 130% |
| Returns for 5 years | 29.63 | 31.80 | 93% |
| Returns for 10 years | 55.33 | 97.43 | 57% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| FBTCX | 28.68 | N/A | N/A |
| Fidelity Advisor Biotechnology C | |||
| AAIEX | 19.69 | -0.10 | -0.51% |
| American Beacon International Eq R5 | |||
| GEMHX | 14.77 | -0.21 | -1.40% |
| Goldman Sachs Emerging Mkts Eq ex. Chn A | |||
| TVOCX | 37.51 | -0.65 | -1.70% |
| Touchstone Small Cap Value C | |||
| ASDEX | 146.97 | -3.26 | -2.17% |
| American Century Select R6 | |||